Residency · Residency · Radiation Oncology
Management of the N0 Neck and Elective Nodal Irradiation
Overview
In head and neck squamous cell carcinoma (HNSCC), a clinically and radiographically node-negative (cN0) neck can still harbor occult metastatic disease in 20-40% of cases. This risk varies depending on factors such as the primary tumor site, T-stage, and histologic characteristics. The decision to treat the N0 neck electively—either by surgery or radiation—or to observe is guided by the estimated likelihood of occult nodal metastasis. Generally, if this risk exceeds 15-20%, elective treatment of the neck is recommended. Elective nodal irradiation (ENI) targets at-risk nodal levels with acceptable morbidity and preserves surgical options for salvage if needed.
Patterns of Nodal Spread by Primary Site
Oral Cavity
The primary lymphatic drainage for oral cavity tumors involves nodal levels I through III, with level I nodes (submandibular and submental) commonly affected. A depth of invasion (DOI) greater than 4 mm strongly predicts occult nodal metastasis, with risk exceeding 20%. The floor of the mouth and oral tongue exhibit the highest rates of occult nodal involvement. Although uncommon, skip metastases to level IV have been reported.
Oropharynx
Oropharyngeal tumors primarily drain to levels II and III, especially the jugulodigastric nodes. There is a high incidence of bilateral nodal involvement, particularly for midline tumors such as those of the base of the tongue and soft palate. Human papillomavirus (HPV)-positive disease often presents with cystic level II nodes. Retropharyngeal nodes (Rouviere nodes) are at risk in tumors involving the posterior pharyngeal wall.
Nasopharynx
Nasopharyngeal cancers typically drain bilaterally to retropharyngeal and levels II through V nodes. At presentation, nodal involvement is very common, occurring in 70-80% of cases. Because of this high risk, bilateral nodal coverage is always indicated, even for tumors confined to one side.
Hypopharynx
Hypopharyngeal tumors spread bilaterally to levels II through IV, with retropharyngeal nodes involved in posterior pharyngeal wall subsites. There is a high rate of contralateral nodal metastasis, even for tumors that are lateralized. Level VI (paratracheal) nodes are at risk when there is subglottic extension.
Larynx
For supraglottic tumors, nodal drainage involves levels II through IV bilaterally, and bilateral treatment is standard except for the most lateralized tumors. Glottic cancers, particularly T1 lesions, have a very low risk of nodal metastasis, so elective neck treatment is not indicated for T1N0 glottic cancers. For T2 glottic tumors with impaired cord mobility or supraglottic extension, levels II through IV are at risk. When there is subglottic extension, level VI (pretracheal and paratracheal) nodes should be considered.
Risk Assessment for Occult Nodal Disease
Clinical and Pathologic Factors
The risk of occult nodal metastasis correlates with several clinical and pathological factors. Higher T-stage tumors carry increased risk. Depth of invasion (DOI) is particularly important in oral cavity cancers; a DOI greater than 4 mm is an upstaging criterion in the AJCC 8th edition and strongly predicts nodal involvement. Other adverse features include perineural invasion (PNI), lymphovascular invasion (LVI), and poor tumor differentiation. Certain primary sites such as the floor of mouth, oral tongue, supraglottis, and hypopharynx are associated with higher nodal risk.
Imaging Assessment
Contrast-enhanced computed tomography (CT) is used to identify suspicious nodes, with criteria including a short axis diameter greater than 1 cm, central necrosis, or rounded morphology. Magnetic resonance imaging (MRI) offers superior soft tissue resolution, particularly for evaluating retropharyngeal nodes and extranodal extension. Positron emission tomography combined with CT (PET-CT) improves sensitivity for detecting small nodes but is limited for nodes smaller than 8 mm. Sentinel lymph node biopsy has been validated for early-stage oral cavity cancers (T1-T2 cN0), allowing identification of occult metastases and guiding the extent of neck dissection while reducing morbidity compared to elective neck dissection.
Elective Nodal Irradiation: Dose and Volume
Dose for Elective Nodal Coverage
The standard elective nodal irradiation dose is 50 Gy delivered in 25 fractions of 2 Gy each. When using simultaneous integrated boost (SIB) techniques, doses of 54-56 Gy over 28-35 fractions are common. Some institutional protocols use 44 Gy in 22 fractions for lower-risk nodal levels. These doses effectively control more than 95% of subclinical disease.
Contouring Guidelines
International consensus guidelines provide detailed recommendations for nodal clinical target volume (CTV) delineation. Gregoire et al. (2003, updated 2014) and Biau et al. (2019) offer European consensus and updated head and neck nodal CTV guidelines, respectively. Typically, the CTV for elective nodal irradiation includes a 5-10 mm expansion around the nodal levels, respecting anatomical boundaries such as bone, air spaces, and uninvolved muscle. Planning target volume (PTV) margins range from 3 to 5 mm depending on immobilization and image-guided radiation therapy (IGRT) techniques.
Level-Specific Delineation
Level IA corresponds to the submental triangle and is at risk for midline oral cavity tumors. Level IB includes the submandibular triangle and is involved in oral cavity and anterior oral tongue cancers. Level II, the upper jugular chain, is at risk for nearly all head and neck sites and is subdivided into IIA and IIB. Level III, the mid-jugular chain, is involved in most head and neck cancers. Level IV, the lower jugular chain, is at risk for hypopharynx, larynx with subglottic extension, and oropharynx tumors. Level V, the posterior triangle, is involved in nasopharynx, posterior oropharynx, and advanced nodal disease. Level VI includes pretracheal and paratracheal nodes, relevant for thyroid, subglottic larynx, and cervical esophageal cancers. Level VII, or superior mediastinal nodes (Stout), is at risk primarily in thyroid and esophageal cancers. Retropharyngeal nodes are at risk in nasopharynx, posterior pharyngeal wall, and oropharynx tumors.
Surgical Management of the N0 Neck
Elective Neck Dissection
Selective neck dissection targeting at-risk nodal levels, either modified radical or selective, is the standard approach for oral cavity cancers that meet risk criteria such as T2 stage or DOI greater than 4 mm. The SENT trial and other studies have demonstrated that sentinel lymph node biopsy is a viable alternative for early-stage oral cavity cancers, reducing morbidity associated with elective neck dissection. Surgical pathology provides critical staging information that guides decisions regarding adjuvant therapy.
Observation
Observation of the N0 neck is appropriate when the risk of occult metastasis is below 15-20%. For example, T1N0 glottic cancers have an occult nodal metastasis rate under 2%, making observation the standard approach. Similarly, T1 superficial oral tongue cancers with DOI less than 4 mm may be observed. This strategy requires rigorous clinical and imaging follow-up to detect any nodal progression promptly.
Special Considerations
Contralateral Neck Treatment
Bilateral neck treatment is standard for midline and near-midline tumors such as those of the base of the tongue, soft palate, supraglottis, and nasopharynx. For well-lateralized tumors, including lateral oral tongue, tonsil, retromolar trigone, and lateral pharyngeal wall cancers, ipsilateral neck treatment may suffice. Sparing the contralateral neck reduces toxicity such as xerostomia and dysphagia but carries a risk of contralateral nodal failure.
Unknown Primary with Cervical Node Metastasis
In cases of unknown primary with cervical node metastasis, p16/HPV-positive status suggests an oropharyngeal origin. In these patients, bilateral irradiation of the palatine tonsils, base of tongue, and neck is indicated. For p16-negative cases, broader mucosal coverage may be necessary, including the nasopharynx, hypopharynx, and larynx in addition to the oropharynx. Emerging data support more limited radiation volumes in p16-positive disease to reduce toxicity.
<image>An anatomical diagram of the lateral neck showing the standardized nodal level classification (levels IA, IB, II, III, IV, V, VI, and retropharyngeal nodes) with color-coded regions. Adjacent to each level are bullet points listing the primary sites for which that level should be included in elective nodal irradiation volumes. The hyoid bone, cricoid cartilage, clavicle, and sternocleidomastoid muscle serve as anatomic landmarks.</image>
<image>A heat-map style table showing the risk of occult nodal metastasis by primary site (rows: oral tongue, floor of mouth, buccal mucosa, retromolar trigone, oropharynx, supraglottic larynx, glottic larynx, hypopharynx, nasopharynx) and T-stage (columns: T1, T2, T3, T4). Cells are color-coded from green (<15%, observation appropriate) through yellow (15-30%) to red (>30%, elective treatment strongly recommended). The 15-20% threshold line is highlighted.</image>
<image>An axial CT image at the level of the hyoid bone with overlaid nodal CTV contours following consensus guidelines. Level IIA (blue), IIB (cyan), retropharyngeal nodes (green), and the primary GTV (red) are delineated. Key anatomic boundaries are labeled: internal jugular vein, sternocleidomastoid muscle, submandibular gland, posterior belly of digastric muscle.</image>
Key Clinical Pearls
The decision to treat the N0 neck electively hinges on a 15-20% threshold for occult nodal disease risk. If the estimated risk exceeds this threshold, elective treatment—either surgical or radiotherapeutic—is recommended. T1N0 glottic cancer exemplifies a scenario where elective neck treatment is not required, given the occult nodal metastasis rate is less than 2%, and small-field radiation therapy targeting the true vocal cords alone is standard. In oral cavity cancers, depth of invasion is the most important predictor of occult nodal metastasis; a DOI greater than 4 mm warrants elective neck treatment and is incorporated into the AJCC 8th edition T-staging. When treating the neck electively with radiation, a dose of 50 Gy in 25 fractions (or an equivalent simultaneous integrated boost dose) is sufficient to sterilize subclinical disease in over 95% of cases, and dose escalation on elective volumes does not confer additional benefit. For midline or near-midline tumors, bilateral neck treatment is always necessary, while unilateral treatment is appropriate only for truly lateralized primaries with low contralateral risk.
References
- Gregoire V et al. "Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines." Radiother Oncol. 2014;110(1):172-181.
- Biau J et al. "Selection of lymph node target volumes for definitive head and neck radiation therapy: a 2019 Update." Radiother Oncol. 2019;134:1-9.
- D'Cruz AK et al. "Elective versus therapeutic neck dissection in node-negative oral cancer." N Engl J Med. 2015;373(6):521-529.
- Schilling C et al. "Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer." Eur J Cancer. 2015;51(18):2777-2784.
- Shah JP. "Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract." Am J Surg. 1990;160(4):405-409.
